
Novo Nordisk is predicting that global sales growth will be negatively impacted by 3 percent in 2022, it reports in a press release on Friday.
This is the result of a new a new insulin procurement model in China, the Volume Based Procurement (VBP) tender, which the Chinese National Healthcare Security Administration has implemented, resulting in lower prices and volumes of insulin sold in China.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app